Peripheral Opioid Receptor Antagonists for Opioid-Induced Constipation: A Primer on Pharmacokinetic Variabilities with a Focus on Drug Interactions

References

• Morlion B, Clemens KE, Dunlop W. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone. Clin Drug Investig. 2015;35(1):1–11. doi:10.1007/s40261-014-0254-6
   Web of Science ®Google Scholar
• Morley KI, Ferris JA, Winstock AR, Lynskey MT. Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data. Pain. 2017;158(6):1138–1144. doi:10.1097/j.pain.0000000000000892
   PubMed Web of Science ®Google Scholar
• Spierings ELH, Brewer RP, Rauck RL, Losch-Beridon T, Mareya SM. Lubiprostone for opioid-induced constipation does not interfere with opioid analgesia in patients with chronic noncancer pain. Pain Pract. 2017;17(3):312–319. doi:10.1111/papr.12444
   Web of Science ®Google Scholar
• Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;328(22):2332–2343. doi:10.1056/NEJMoa0707377
   Web of Science ®Google Scholar
• Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387–2396. doi:10.1056/NEJMoa1310246
   PubMed Web of Science ®Google Scholar
• Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, Phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017;2(8):555–564. doi:10.1016/S2468-1253(17)30105-X
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv Drug Deliv Rev. 1995;15(1–3):5–36. doi:10.1016/0169-409X(95)00003-P
   Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3–14. doi:10.1602/neurorx.2.1.3
   PubMedGoogle Scholar
• Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959–1972. doi:10.1038/jcbfm.2012.126
   PubMed Web of Science ®Google Scholar
• Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26(10):1386–1395. doi:10.1111/nmo.12417
   PubMed Web of Science ®Google Scholar
• Lund M, Petersen TS, Dalhoff KP. Clinical implications of P-glycoprotein modulation in drug–drug interactions. Drugs. 2017;77(8):859–883. doi:10.1007/s40265-017-0729-x
   PubMed Web of Science ®Google Scholar
• Arnold RJG, Tang J, Schrecker J, Hild C. Impact of definitive drug–drug interaction testing on medication management and patient care. Drugs Real World Outcomes. 2018;5(4):217–224. doi:10.1007/s40801-018-0143-z
   Google Scholar
• Taxak N, Bharatam PV. Drug metabolism: a fascinating link between chemistry and biology. Resonance. 2014;19(3):259–282. doi:10.1007/s12045-014-0031-0
   Google Scholar
• Gunaratna C. Drug metabolism & pharmacokinetics in drug discovery: a primer for bioanalytical chemists, part I. Curr Sep. 2000;19(1):17–23.
   Google Scholar
• Nassar AF, Hollenberg PF, Scatina J. Drug Metabolism Handbook: Concepts and Applications. Hoboken, NJ: John Wiley & Sons, Inc.; 2009.
   Google Scholar
• McDonnell AM, Dang CH. Basic review of the cytochrome P450 system. J Adv Pract Oncol. 2013;4(4):263–268. doi:10.6004/jadpro.2013.4.4.7
   PubMedGoogle Scholar
• Shapiro K, Brown SA, Garrett SD. Drug interactions. In: RxPrep Course Book: A Comprehensive Course for the NAPLEX and CPJE. El Segundo, CA: RxPrep; 2015:190–202.
   Google Scholar
• Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9(4):310–322. doi:10.2174/138920008784220664
   PubMed Web of Science ®Google Scholar
• Guidance for industry: clinical drug interaction studies – study design, data analysis, and clinical implications; 2017. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf. Accessed June 18, 2019.
   Google Scholar
• Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42(1):59–98. doi:10.2165/00003088-200342010-00003
   PubMed Web of Science ®Google Scholar
• Metcalf MD, Rosicky AD, Hassan HE, et al. Opioids and efflux transporters. Part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues. Bioorg Med Chem Lett. 2014;24(15):3592–3595. doi:10.1016/j.bmcl.2014.05.033
   Web of Science ®Google Scholar
• Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000;38(2):69–74. doi:10.5414/CPP38069
   PubMed Web of Science ®Google Scholar
• Chaves C, Remiao F, Cisternino S, Decleves X. Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain. Curr Neuropharmacol. 2017;15(8):1156–1173. doi:10.2174/1570159X15666170504095823
   PubMed Web of Science ®Google Scholar
• Kolbow J, Modess C, Wegner D, et al. Extended-release but not immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in healthy subjects. J Clin Pharmacol. 2016;56(2):239–245. doi:10.1002/jcph.v56.2
   Web of Science ®Google Scholar
• Glaeser H. Importance of P-glycoprotein for drug–drug interactions. Handb Exp Pharmacol. 2011;(201):285–297.
   Google Scholar
• Fortuna A, Alves G, Falcao A. In vitro and in vivo relevance of the P-glycoprotein probe substrates in drug discovery and development: focus on rhodamine 123, digoxin and talinolol. J Bioequiv Availab. 2011;(suppl 2). doi:10.4172/jbb.S2-001
   Google Scholar
• Mercer SL, Coop A. Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem. 2011;11(9):1157–1164. doi:10.2174/156802611795371288
   Web of Science ®Google Scholar
• Cunningham CW, Mercer SL, Hassan HE, Traynor JR, Eddington ND, Coop A. Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs. J Med Chem. 2008;51(7):2316–2320. doi:10.1021/jm701457j
   Web of Science ®Google Scholar
• Mercer SL, Hassan HE, Cunningham CW, Eddington ND, Coop A. Opioids and efflux transporters. Part 1: P-glycoprotein substrate activity of N-substituted analogs of meperidine. Bioorg Med Chem Lett. 2007;17(5):1160–1162. doi:10.1016/j.bmcl.2006.12.042
   Web of Science ®Google Scholar
• Horn JR, Hansten P. Drug transporters: the final frontier for drug interactions. Pharm Times. 2008;2:33.
   Google Scholar
• Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther. 2017;59(1517):e56.
   Google Scholar
• Lin JH. Drug–drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev. 2003;55(1):53–81. doi:10.1016/S0169-409X(02)00171-0
   PubMed Web of Science ®Google Scholar
• Ased S, Wells J, Morrow LE, Malesker MA. Clinically significant food–drug interactions. Consult Pharm. 2018;33(11):649–657. doi:10.4140/TCP.n.2018.649.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol. 2004;18(2):262–276. doi:10.1177/0269881104042632
   PubMed Web of Science ®Google Scholar
• Sasaki T, Sato Y, Kumagai T, Yoshinari K, Nagata K. Effect of health foods on cytochrome P450-mediated drug metabolism. J Pharm Health Care Sci. 2017;3:14. doi:10.1186/s40780-017-0083-x
   Web of Science ®Google Scholar
• Mouly S, Lloret-Linares C, Sellier PO, Sene D, Bergmann JF. Is the clinical relevance of drug–food and drug–herb interactions limited to grapefruit juice and Saint-John’s Wort? Pharmacol Res. 2017;118:82–92. doi:10.1016/j.phrs.2016.09.038
   PubMed Web of Science ®Google Scholar
• Relistor [package insert]. Bridgewater, NJ: Salix Pharmaceuticals; 2018.
   Google Scholar
• Movantik [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2018.
   Google Scholar
• Symproic [package insert]. Florham Park, NJ: Shionogi Inc.; 2018.
   Google Scholar
• Effects of MNTX on CYP450 2D6 in metabolizers of dextromethorphan NCT01367535; 2011. Available from: https://clinicaltrials.gov/ct2/show/NCT01367535. Accessed August 29, 2018.
   Google Scholar
• Effect of cimetidine on the single-dose PK of IV- administered MNTX NCT01366378; 2011. Available from: https://clinicaltrials.gov/ct2/show/NCT01366378. Accessed August 29, 2018.
   Google Scholar
• Flerlage JE, Baker JN. Methylnaltrexone for opioid-induced constipation in children and adolescents and young adults with progressive incurable cancer at the end of life. J Palliat Med. 2015;18(7):631–633. doi:10.1089/jpm.2014.0364
   Web of Science ®Google Scholar
• Bui K, Zhou D, Sostek M, She F, Al-Huniti N. Effects of CYP3A modulators on the pharmacokinetics of naloxegol. J Clin Pharmacol. 2016;56(8):1019–1027. doi:10.1002/jcph.v56.8
   Web of Science ®Google Scholar
• Zhou D, Bui K, Sostek M, Al-Huniti N. Simulation and prediction of the drug–drug interaction potential of naloxegol by physiologically based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol. 2016;5(5):250–257. doi:10.1002/psp4.12070
   Google Scholar
• Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain. 2013;154(9):1542–1550. doi:10.1016/j.pain.2013.04.024
   PubMed Web of Science ®Google Scholar
• Yu J, Ritchie TK, Zhou Z, Ragueneau-Majlessi I. Key findings from preclinical and clinical drug interaction studies presented in new drug and biological license applications approved by the food and drug administration in 2014. Drug Metab Dispos. 2016;44(1):83–101. doi:10.1124/dmd.115.066720
   PubMed Web of Science ®Google Scholar
• Bui K, She F, Zhou D, Butler K, Al-Huniti N, Sostek M. The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. J Clin Pharmacol. 2016;56(4):497–505. doi:10.1002/jcph.v56.4
   Web of Science ®Google Scholar
• US Food and Drug Administration and Center for Drug Evaluation and Research. Naloxegol medical review; 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204760Orig1s000MedR.pdf. Accessed June 20, 2017.
   Google Scholar
• US Food and Drug Administration and Center for Drug Evaluation and Research. Naldemedine clinical pharmacology and biopharmaceutics review; 2008. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021964s000_PharmR_P1.pdf. Accessed August 29, 2018.
   Google Scholar
• Liu JC, Ma JD, Morello CM, Atayee RS, Best BM. Naltrexone metabolism and concomitant drug concentrations in chronic pain patients. J Anal Toxicol. 2014;38(4):212–217. doi:10.1093/jat/bku019
   PubMed Web of Science ®Google Scholar
• Targiniq ER [package insert]. Stamford, CT: Purdue Pharma; 2014.
   Google Scholar
• Zubsolv [package insert]. Morristown, NJ: Orexo US; 2018.
   Google Scholar
• Talwin Nx [package insert]. Bridgewater, NJ: Sanofi-aventis U.S.; 2011.
   Google Scholar
• European Medicines Agency. Assessment report: oxynal-Targin and associated names 2014. Available from: https://www.ema.europa.eu/documents/referral/oxynal-targin-article-13-referral-assessment-report_en.pdf. Accessed October 12, 2018.
   Google Scholar
• Smith K, Hopp M, Mundin G, et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs. 2011;20(4):427–439. doi:10.1517/13543784.2011.563236
   PubMed Web of Science ®Google Scholar
• Lowenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10(4):531–543. doi:10.1517/14656560902796798
   PubMed Web of Science ®Google Scholar
• Suboxone Sublingual Film [package insert]. North Chesterfield, VA: Indivior Inc.; 2018.
   Google Scholar
• Suboxone [summary of product characteristics]. Dublin, Ireland: Indivior Europe Limited; 2018.
   Google Scholar
• Zubsolv [summary of product characteristics]. Cambridge, United Kingdom: Mundipharma Corporation Limited; 2018.
   Google Scholar